Edward T. Mathers's Insider Trades & SAST Disclosures
Edward T. Mathers's most recent trade in OnKure Therapeutics Inc. - Ordinary Shares - Class A was a trade of 2,580 Class A Common Stock done . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Edward T. Mathers.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OnKure Therapeutics Inc. -... | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 2,580 | 2,580 | - | 0 | Class A Common Stock | |
| Senti Biosciences Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 43,900 | 43,900 | - | - | Stock Option (Right to Buy) | |
| OnKure Therapeutics Inc. -... | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
| NeueHealth Inc. | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 01 Oct 2024 | 185,595 | 556,782 | - | - | Warrant (Right to Buy) | |
| NeueHealth Inc. | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 01 Oct 2024 | 61,865 | 185,594 | - | - | Warrant (Right to Buy) | |
| MBX Biosciences Inc. | Edward T. Mathers | Director, Ten Percent Owner | 16 Sep 2024 | 25,142,840 | 0 | - | - | Series B Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Edward T. Mathers | Director, Ten Percent Owner | 16 Sep 2024 | 12,299,854 | 0 | - | - | Series A Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Edward T. Mathers | Director, Ten Percent Owner | 16 Sep 2024 | 2,091,383 | 3,114,486 | - | - | Common Stock | ||
| MBX Biosciences Inc. | Edward T. Mathers | Director, Ten Percent Owner | 16 Sep 2024 | 1,023,103 | 1,023,103 | - | - | Common Stock | ||
| MBX Biosciences Inc. | Edward T. Mathers | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 16 Sep 2024 | 500,000 | 3,614,486 | - | 16 | 8,000,000 | Common Stock |
| MBX Biosciences Inc. | Edward T. Mathers | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 15,963 | 15,963 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2024 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 3,000 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 0 | - | - | Restricted Stock Units | |
| Inozyme Pharma Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Trevi Therapeutics Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| NeueHealth Inc. | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Apr 2024 | 371,187 | 371,187 | - | - | Warrant (Right to Buy) | |
| NeueHealth Inc. | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Apr 2024 | 123,729 | 123,729 | - | - | Warrant (Right to Buy) | |
| Bright Health Group Inc | T. Edward Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Dec 2023 | 175,525 | 1,656,789 | - | - | Warrant (Right to Buy) | |
| Bright Health Group Inc | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Oct 2023 | 100,606 | 1,481,264 | - | - | Warrant (Right to Buy) | |
| Bright Health Group Inc | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Sep 2023 | 552,263 | 1,380,658 | - | - | Warrant (Right to Buy) | |
| Bright Health Group Inc | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Aug 2023 | 828,395 | 828,395 | - | - | Warrant (Right to Buy) | |
| Trevi Therapeutics Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Synlogic Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Senti Biosciences Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Other type of transaction at price $ 0.00 per share. | 02 Mar 2023 | 5,771 | 5,771 (0%) | 0% | 0 | Common Stock | |
| Bright Health Group Inc | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Oct 2022 | 100,000 | 100,000 | - | - | Series B Convertible Perpetual Preferred Stock | |
| Bright Health Group Inc | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Oct 2022 | 37,700 | 37,700 | - | - | Series B Convertible Perpetual Preferred Stock | |
| Senti Biosciences Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Trevi Therapeutics Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Inozyme Pharma Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Synlogic Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 3,000,000 | 3,000,000 | - | - | Pre-Funded Warrants | |
| Trevi Therapeutics Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 1.90 per share. | 11 Apr 2022 | 948,948 | 948,948 (5%) | 5% | 1.9 | 1,803,001 | Common Stock |
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | 28 Jun 2021 | 11,500,000 | 0 | - | - | Series B convertible preferred stock | ||
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | 28 Jun 2021 | 9,588,725 | 0 | - | - | Series A-2 convertible preferred stock | ||
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | 28 Jun 2021 | 3,257,328 | 5,973,296 | - | - | Common Stock | ||
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | 28 Jun 2021 | 2,715,968 | 2,715,968 | - | - | Common Stock | ||
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | 28 Jun 2021 | 2,361,912 | 0 | - | - | Series C convertible preferred Stock | ||
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 28 Jun 2021 | 1,050,000 | 7,692,298 | - | 19 | 19,950,000 | Common Stock |
| Monte Rosa Therapeutics Inc | Edward T. Mathers | Ten Percent Owner | 28 Jun 2021 | 669,002 | 6,642,298 | - | - | Common Stock | ||
| Inozyme Pharma Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2021 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Edward T. Mathers | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Edward T. Mathers | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) | |
| Synlogic Inc | Edward T. Mathers | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges